Broens Bo, Nossent Esther J, Meijboom Lilian J, Zwezerijnen Gerben J C, Spierings Julia, de Vries-Bouwstra Jeska K, van Laar Jacob M, van der Laken Conny J, Voskuyl Alexandre E
Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Meibergdreef 9, Room G7-126, Amsterdam, 1105 AZ, the Netherlands.
Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Arthritis Res Ther. 2024 Dec 19;26(1):219. doi: 10.1186/s13075-024-03447-x.
This study aimed to assess the quantitative uptake of F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung disease (ILD), compared to controls. In patients with SSc-ILD, F-FDG uptake was correlated to high-resolution computed tomography (HRCT) and pulmonary function test (PFT) parameters.
A prospective, cross-sectional study was conducted, involving 15 patients with SSc-ILD, 5 patients with SSc without ILD, and 7 controls without SSc. F-FDG PET-CT scans were performed following standardized protocols, and quantitative analysis of tracer uptake was conducted in predefined lung regions. In addition, HRCT scans were evaluated for ILD-related radiologic abnormalities. Between-group differences were compared with non-parametric tests, while correlations with PFT parameters were analyzed using Spearman correlation coefficients.
F-FDG uptake was mainly increased in the dorsobasal lung fields of patients with SSc-ILD compared to SSc without ILD and controls (p = 0.03 and p < 0.001, respectively). F-FDG uptake was higher in SSc patients with extensive ILD (≥ 20% vs < 20%, p = 0.04) and correlated with lower DLCO% (R = -0.59, p = 0.02). Ground-glass opacities, with or without reticulation, corresponded to increased F-FDG uptake.
F-FDG PET-CT can detect metabolic activity in the lungs of patients with early severe diffuse cutaneous SSc and ILD, correlating with higher ILD extent (≥ 20%) and lower DLCO%. These results suggest the potential utility of F-FDG PET-CT in the early detection of ILD (progression) and aiding in risk stratification.
本研究旨在评估早期重度弥漫性皮肤系统性硬化症(SSc)伴或不伴间质性肺疾病(ILD)患者肺部F-FDG PET-CT的定量摄取情况,并与对照组进行比较。在SSc-ILD患者中,F-FDG摄取与高分辨率计算机断层扫描(HRCT)和肺功能测试(PFT)参数相关。
进行了一项前瞻性横断面研究,纳入15例SSc-ILD患者、5例无ILD的SSc患者和7例无SSc的对照者。按照标准化方案进行F-FDG PET-CT扫描,并在预定义的肺区域进行示踪剂摄取的定量分析。此外,对HRCT扫描进行评估以发现与ILD相关的放射学异常。组间差异采用非参数检验进行比较,与PFT参数的相关性采用Spearman相关系数进行分析。
与无ILD的SSc患者和对照组相比,SSc-ILD患者的F-FDG摄取主要在肺背底部区域增加(分别为p = 0.03和p < 0.001)。广泛ILD(≥20% vs < 20%)的SSc患者F-FDG摄取更高(p = 0.04),且与较低的DLCO%相关(R = -0.59,p = 0.02)。磨玻璃影,无论有无网状影,均对应F-FDG摄取增加。
F-FDG PET-CT可检测早期重度弥漫性皮肤SSc和ILD患者肺部的代谢活性,与更高的ILD范围(≥20%)和更低的DLCO%相关。这些结果表明F-FDG PET-CT在ILD(进展)的早期检测和协助风险分层方面具有潜在应用价值。